SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-20-014540
Filing Date
2020-12-23
Accepted
2020-12-23 17:01:11
Documents
93
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-K otlk-20200930x10k.htm 10-K 2041936
2 EX-4.1 otlk-20200930ex413bd0582.htm EX-4.1 45865
3 EX-23.1 otlk-20200930ex2313a8c80.htm EX-23.1 3726
4 EX-31.1 otlk-20200930ex31119a64e.htm EX-31.1 13625
5 EX-32.1 otlk-20200930ex32166d013.htm EX-32.1 7799
6 GRAPHIC otlk-20200930x10k006.jpg GRAPHIC 26065
  Complete submission text file 0001558370-20-014540.txt   9462522

Data Files

Seq Description Document Type Size
7 EX-101.INS otlk-20200930.xml EX-101.INS 2030210
8 EX-101.SCH otlk-20200930.xsd EX-101.SCH 66968
9 EX-101.CAL otlk-20200930_cal.xml EX-101.CAL 68294
10 EX-101.DEF otlk-20200930_def.xml EX-101.DEF 301257
11 EX-101.LAB otlk-20200930_lab.xml EX-101.LAB 552148
12 EX-101.PRE otlk-20200930_pre.xml EX-101.PRE 533321
Mailing Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852
Business Address 4260 U.S. ROUTE 1 MONMOUTH JUNCTION NJ 08852 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-K | Act: 34 | File No.: 001-37759 | Film No.: 201413323
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences